hivaid
result
death
million
person
throughout
world
lead
caus
death
among
person
year
age
approxim
million
person
estim
live
hiv
infect
unit
state
estim
million
person
infect
hiv
new
infect
occur
year
sinc
recognit
diseas
kill
half
million
peopl
unit
state
despit
grim
statist
reason
hope
exist
basic
research
yield
major
insight
pathogen
mechan
hiv
diseas
knowledg
pave
way
develop
antiretrovir
medic
approv
food
drug
administr
fda
target
hiv
well
novel
strategi
prevent
vaccin
develop
use
combin
drug
target
differ
protein
involv
hiv
pathogenesi
treatment
strategi
known
highli
activ
antiretrovir
therapi
haart
rate
death
ill
unit
state
industri
countri
dramat
reduc
figur
although
death
rate
due
hivaid
europ
north
america
fallen
sinc
haart
introduc
rel
peopl
poor
countri
reap
benefit
new
initi
global
fund
fight
aid
tuberculosi
malaria
presid
emerg
plan
aid
relief
promis
greatli
reduc
dispar
rich
poor
countri
regard
access
hiv
treatment
care
prevent
servic
greatest
challeng
hivaid
research
remain
develop
vaccin
either
prevent
transmiss
viru
fail
halt
progress
aid
sinc
niaid
fund
clinic
trial
evalu
differ
hiv
vaccin
candid
unfortun
first
largescal
phase
trial
hiv
vaccin
report
disappoint
result
mani
differ
vaccin
strategi
includ
viral
bacteri
vector
dna
vaccin
viruslik
particl
vaccin
peptid
vaccin
investig
clinic
trial
human
way
effect
variou
adjuv
differ
rout
administr
also
test
hiv
vaccin
develop
face
formid
scientif
obstacl
includ
viru
genet
divers
lack
clear
understand
correl
protect
immun
hiv
infect
critic
far
elus
mileston
discoveri
stabl
immunogen
conform
epitop
hiv
envelop
would
elicit
broadli
reactiv
neutral
antibodi
primari
isol
hiv
overcom
challeng
collabor
involv
govern
academia
industri
philanthropi
new
crosssector
partnership
global
hiv
vaccin
enterpris
virtual
consortium
independ
organ
establish
advanc
hiv
vaccin
research
foster
greater
collabor
among
hiv
vaccin
research
worldwid
social
econom
human
toll
exact
malaria
global
widespread
profound
year
acut
malaria
occur
million
peopl
result
million
death
worldwid
death
occur
young
children
live
subsaharan
africa
human
diseas
caus
one
speci
plasmodium
singlecel
parasit
transmit
anophelin
mosquito
complet
genom
sequenc
plasmodium
falciparum
well
mosquito
vector
anophel
gambia
complet
result
multin
effort
genom
sequenc
parasit
human
mosquito
host
avail
research
power
tool
character
gene
protein
involv
life
cycl
parasit
use
inform
design
effect
drug
vaccin
drugresist
plasmodium
strain
widespread
insecticideresist
strain
mosquito
carri
parasit
mutat
parasit
mosquito
confer
drug
insecticid
resist
identifi
exampl
genet
analysi
molecular
epidemiolog
studi
p
falciparum
shown
resist
chloroquin
antimalari
caus
mutat
singl
gene
call
pfcrt
inform
use
track
spread
drugresist
strain
parasit
identifi
new
drug
target
research
also
exploit
new
genom
inform
creat
genet
alter
mosquito
resist
parasit
infect
develop
new
compound
overcom
avoid
resist
exist
pesticid
develop
effect
antimalari
vaccin
challeng
howev
intern
research
team
recent
develop
vaccin
show
promis
prevent
malaria
among
children
mozambiqu
vaccin
prevent
infect
sever
diseas
substanti
percentag
children
test
breakthrough
potenti
save
million
live
specif
vaccin
efficaci
first
clinic
episod
confid
interv
ci
p
vaccin
efficaci
sever
malaria
ci
p
addit
least
malaria
vaccin
candid
undergon
phase
clinic
trial
human
move
advanc
clinic
develop
preclin
develop
dozen
candid
support
anoth
ancient
microbi
scourg
reemerg
recent
year
tuberculosi
tb
caus
infect
bacterium
mycobacterium
tuberculosi
infect
estim
preval
one
third
world
popul
reservoir
million
new
case
tb
develop
worldwid
year
carri
death
toll
million
tb
especi
preval
among
person
infect
hiv
current
avail
tb
vaccin
bovi
bacillu
bcg
offer
protect
effect
diminish
time
tb
drug
treatment
effect
adher
lengthi
therapeut
regimen
difficult
maintain
multidrugresist
tb
rise
mani
countri
research
appli
stateoftheart
genom
postgenom
techniqu
identifi
key
molecular
pathway
could
exploit
develop
improv
tb
intervent
vaccin
first
time
year
new
vaccin
design
prevent
tb
enter
phase
clinic
trial
unit
state
mani
promis
new
antitb
drug
candid
also
enter
drug
pipelin
deriv
known
antitb
drug
thiolactomycin
ethambutol
current
screen
activ
tuberculosi
preclin
develop
highli
promis
candid
near
complet
year
influenza
develop
american
hospit
diseas
although
influenza
commonplac
gener
selflimit
estim
american
die
year
complic
diseas
worldwid
sever
influenza
infect
develop
million
peopl
annual
death
occur
outbreak
avian
influenza
recent
drawn
attent
worldwid
particularli
southeast
asia
least
person
infect
die
sinc
januari
current
strain
avian
influenza
highli
pathogen
kill
million
chicken
bird
although
viru
cross
speci
infect
human
suspect
case
humantohuman
transmiss
report
howev
viru
could
acquir
characterist
allow
readili
transmit
among
human
could
caus
worldwid
influenza
pandem
potenti
kill
million
peopl
pandem
spanish
flu
kill
million
peopl
worldwid
recent
nih
influenza
genom
project
initi
conduct
rapid
sequenc
complet
genom
sever
thousand
known
avian
human
influenza
virus
well
emerg
futur
approxim
genom
expect
sequenc
month
project
also
illumin
molecular
basi
new
strain
influenza
viru
emerg
provid
inform
characterist
contribut
increas
virul
mani
research
believ
viru
show
greatest
potenti
evolv
next
human
pandem
strain
avian
virus
also
infect
human
potenti
caus
pandem
prepar
possibl
develop
vaccin
prevent
infect
viral
strain
support
research
also
work
develop
liveattenu
vaccin
candid
direct
hemagglutinin
protein
isol
effort
may
speed
develop
vaccin
potenti
pandem
strain
use
revers
genet
research
develop
genet
engin
vaccin
candid
call
refer
viru
matter
week
demonstr
power
technolog
new
candid
test
anim
confirm
longer
highli
pathogen
vaccin
manufactur
use
refer
viru
develop
inactiv
vaccin
evalu
phase
clinic
trial
revers
genet
also
use
identifi
specif
genet
mutat
viral
gene
call
make
viru
especi
lethal
discoveri
may
use
design
antivir
drug
vaccin
candid
experi
also
conduct
gene
isol
influenza
strain
clone
avirul
influenza
strain
research
recent
show
hemagglutinin
gene
viru
confer
high
degre
pathogen
avirul
influenza
strain
introduc
mice
recombin
virus
other
evalu
variou
anim
model
includ
nonhuman
primat
determin
gene
viru
contribut
abil
spread
rapidli
caus
mani
death
understand
molecular
basi
unpreced
virul
previou
research
establish
foundat
develop
liveattenu
nasal
flu
vaccin
approv
fda
use
healthi
adult
children
year
age
west
nile
viru
wnv
long
endem
africa
west
asia
europ
middl
east
repres
reemerg
diseas
recent
arriv
unit
state
viru
first
appear
new
york
citi
area
wnvrelat
diseas
report
person
continu
spread
throughout
unit
state
subsequ
summer
infect
ever
larger
popul
particularli
research
led
sever
promis
vaccin
candid
wnv
one
base
licens
yellow
fever
vaccin
viru
contain
wnv
gene
test
nonhuman
primat
current
evalu
human
clinic
trial
second
vaccin
develop
nih
use
attenu
dengu
viru
wnv
gene
insert
vaccin
protect
monkey
hors
wnv
infect
clinic
trial
underway
subunit
dna
vaccin
wnv
also
variou
stage
develop
test
sever
innov
therapi
also
test
treat
person
alreadi
infect
wnv
clinic
trial
site
across
unit
state
canada
protect
effect
immunoglobulin
product
test
hospit
patient
high
risk
wnv
enceph
technolog
also
develop
screen
larg
number
chemic
compound
antivir
activ
februari
compound
screen
vitro
shown
antivir
activ
wnv
compound
undergo
evalu
hamster
mous
model
diseas
partnership
small
biotechnolog
compani
form
develop
sensit
rapid
test
detect
wnv
infect
studi
ongo
evalu
role
variou
mosquito
vector
anim
reservoir
viru
transmiss
test
novel
mosquito
control
method
limit
impact
insecticid
resist
mosquito
control
emerg
sar
asia
late
speed
character
contain
underscor
import
cooper
research
public
health
offici
niaid
focus
resourc
develop
diagnost
vaccin
novel
antivir
compound
combat
sarscov
basic
research
pathogenesi
diseas
identifi
appropri
target
therapeut
vaccin
well
clinic
studi
test
new
therapi
also
support
among
mani
project
receiv
support
develop
sar
chip
dna
microarray
rapidli
identifi
sar
sequenc
variant
sar
diagnost
test
base
polymeras
chain
reaction
technolog
research
develop
candid
vaccin
base
sarscov
spike
protein
protect
mice
sar
anoth
promis
vaccin
protect
infect
monkey
deliv
intranas
passiv
immun
treatment
sar
patient
also
investig
mous
human
antibodi
sar
prevent
infect
introduc
uninfect
mice
intern
collabor
develop
rapid
method
produc
human
antisar
antibodi
vitro
screen
chemic
identifi
compound
activ
sarscov
least
select
industri
candid
clinic
develop
septemb
attack
world
trade
center
pentagon
subsequ
anthrax
attack
infect
peopl
kill
propel
us
govern
expand
biodefens
research
program
studi
base
approach
basic
research
aim
understand
structur
biolog
mechan
potenti
bioweapon
caus
diseas
studi
elucid
human
immun
system
respond
danger
pathogen
develop
technolog
translat
basic
studi
safe
effect
countermeasur
detect
prevent
treat
diseas
caus
pathogen
least
major
niaid
initi
involv
intramur
extramur
scientist
industri
partner
fund
fiscal
year
among
fund
region
center
excel
biodefens
emerg
infecti
diseas
research
construct
nation
biocontain
laboratori
region
biocontain
laboratori
facil
provid
secur
space
need
carri
nation
expand
biodefens
research
program
genom
biolog
agent
consid
pose
sever
threat
sequenc
research
addit
program
expand
contract
award
screen
new
chemic
compound
possibl
treatment
bioterror
attack
new
anim
model
develop
test
promis
drug
repositori
establish
catalog
reagent
specimen
addit
research
understand
bodi
protect
mechan
pathogen
pursu
cooper
center
translat
research
human
immunolog
biodefens
focu
studi
human
immun
respons
potenti
agent
bioterror
program
focus
innat
immun
system
develop
way
boost
innat
immun
niaid
also
activ
vaccin
develop
biodefens
countermeasur
institut
support
develop
nextgener
anthrax
vaccin
known
recombin
protect
antigen
rpa
undergo
clinic
trial
contract
strateg
nation
stockpil
acquir
recent
award
sever
new
smallpox
vaccin
also
test
safeti
efficaci
preliminari
studi
mice
monkey
show
one
modifi
vaaccinia
ankara
mva
protect
poxviru
infect
clinic
trial
mva
vaccin
ongo
niaid
vaccin
research
center
elsewher
clinic
trial
novel
dna
vaccin
ebola
viru
also
way
human
test
adenovirusvector
ebola
vaccin
plan
vaccin
manufactur
clinic
trial
also
plan
new
recombin
vaccin
plagu
highli
effect
mice
nonhuman
primat
academ
togeth
industri
partner
intern
made
great
stride
past
year
understand
mani
pathogen
mechan
emerg
reemerg
infecti
diseas
mani
discoveri
translat
novel
diagnost
antivir
antimicrobi
compound
vaccin
often
extraordinari
speed
howev
mani
challeng
remain
paramount
among
develop
safe
effect
hiv
vaccin
evolut
pathogen
resist
antibacteri
antivir
agent
continu
challeng
us
better
understand
mechan
drug
resist
devis
new
way
circumv
problem
effort
pave
way
develop
countermeasur
deliber
engin
microb
histori
guid
assum
battl
intellect
human
speci
extraordinari
adapt
microb
neverend
success
fight
microbi
foe
must
continu
vigor
pursu
research
basic
mechan
underli
microbi
pathogenesi
develop
novel
strategi
outwit
these
ingeni
oppon
past
year
challeng
futur
